Clinical Trials Logo

Clinical Trial Summary

Specific phobias and other anxiety disorders represent a major mental health problem, and present a significant challenge to researchers because effective treatment usually involves repeated exposure to feared stimuli, and the high levels of associated distress can lead to termination of treatment. Recent advances in computational functional magnetic resonance imaging (fMRI) provide a method by which individuals may be unconsciously exposed to fearful stimuli, leading to effective fear reduction while eliminating a primary cause of attrition. The objective of the current study is to use the novel approach of neuro-reinforcement based on decoded fMRI information to reduce fear responses to fearful stimuli (e.g., spiders, heights) in individuals with phobias, directly and unconsciously in the brain, without repeatedly exposing participants to their feared stimuli. Participants will be randomized into one of three groups of varying neuro-reinforcement sessions (1, 3, or 5). They will complete tests of subjective fear and directed attention while being scanned by fMRI to measure engagement of amygdala activity to fearful stimuli as well as measured through other indicators of fear such as skin conductance response.


Clinical Trial Description

Anxiety disorders, the most common group of mental disorders in the United States, represent a major mental health problem. Phobias, in which fear and anxiety are triggered by a specific stimulus or situation, are the largest category of anxiety disorders and affect 5 - 12% of the world's population. Exposure-based therapies are effective in reducing symptoms, but their effectiveness depends on the individual's capacity or willingness to consciously confront their feared object. The associated distress can be so extreme that it prevents patients from seeking treatment, and contributes to attrition from exposure once treatment begins. As a result, there is an unmet need for treatment that minimizes attrition and subjective patient discomfort. The current study uses a novel technique of neuro-reinforcement based on decoded fMRI information to reduce fear responses to fearful stimuli directly and unconsciously without repeatedly exposing participants to those stimuli. The goals are to (1) confirm that our method decreases amygdala reactivity to images of phobic stimuli as well as (2) determine dosage-response optimization. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03655262
Study type Interventional
Source University of California, Los Angeles
Contact
Status Completed
Phase N/A
Start date October 1, 2018
Completion date June 30, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04977544 - Virtual Reality Exposure Therapy in the Intensive Treatment of Social Anxiety Disorder N/A
Completed NCT03658252 - Efficacy of Targeted Intervention for Topical Steroid Phobia. N/A
Completed NCT00451750 - Cortisol in the Treatment of Phobias N/A
Completed NCT04782570 - Psychotherapy of Anxiety Disorders With Noninvasive Brain Stimulation - Using Virtual Reality N/A
Recruiting NCT03528109 - Improving Access to Child Anxiety Treatment N/A
Not yet recruiting NCT03813823 - Biobehavioral Correlates of Acute Phobic Fear
Completed NCT02810171 - Dimensional Brain Behavior Predictors of CBT Outcomes in Pediatric Anxiety N/A
Completed NCT02223767 - TMS Augmented Exposure Therapy N/A
Terminated NCT04019054 - TMS and Exposure Therapy N/A
Recruiting NCT03498599 - Neuroimaging of Pavlovian Fear Conditioning Processes in Patients With Pathological Anxiety N/A